Complex therapy of patients with chronic lower limb ischemia by angiogenesis gene inductors:immediate and long-term results
- Authors: Gavrilenko, AV1, Voronov, DA1, Bochkov NP1
-
Affiliations:
- B.V. Petrovsky Russian Scientific Center of Surgery, RAMS
- Issue: Vol 6, No 3 (2011)
- Pages: 84-88
- Section: Articles
- URL: https://genescells.ru/2313-1829/article/view/121560
- DOI: https://doi.org/10.23868/gc121560
- ID: 121560
Cite item
Open Access
Access granted
Subscription or Fee Access
Abstract
The controlled study results of using therapeutic
angiogenesis in multimodality therapy of patients with chronic
lower limb ischemia (CLLI) are presented. 134 patients (74
ones comprised the target group and 60 patients were the
controls) with CLLI IIb-III stages according to the Fontaine-
Pokrovsky classification were included into the study.
Angiogenesis stimulation was used both as a separate
treatment modality in combination with routine conservative
therapy and as an adjuvant to reconstructive vascular
surgery. It is proved that genetically engineered angiogenesis
stimulators can be used in a multimodality therapy of patients
with CLLI, demonstrating satisfactory tolerance and safety.
Therapeutic angiogenesis technologies have been shown to
be applied as an independent therapy and as in combination
with reconstructive vascular surgery to improve a long-term
outcome of the latter.
angiogenesis in multimodality therapy of patients with chronic
lower limb ischemia (CLLI) are presented. 134 patients (74
ones comprised the target group and 60 patients were the
controls) with CLLI IIb-III stages according to the Fontaine-
Pokrovsky classification were included into the study.
Angiogenesis stimulation was used both as a separate
treatment modality in combination with routine conservative
therapy and as an adjuvant to reconstructive vascular
surgery. It is proved that genetically engineered angiogenesis
stimulators can be used in a multimodality therapy of patients
with CLLI, demonstrating satisfactory tolerance and safety.
Therapeutic angiogenesis technologies have been shown to
be applied as an independent therapy and as in combination
with reconstructive vascular surgery to improve a long-term
outcome of the latter.
About the authors
A V Gavrilenko,
B.V. Petrovsky Russian Scientific Center of Surgery, RAMSB.V. Petrovsky Russian Scientific Center of Surgery, RAMS
D A Voronov,
B.V. Petrovsky Russian Scientific Center of Surgery, RAMSB.V. Petrovsky Russian Scientific Center of Surgery, RAMS
N P Bochkov
B.V. Petrovsky Russian Scientific Center of Surgery, RAMSB.V. Petrovsky Russian Scientific Center of Surgery, RAMS
References
- Бокерия Л.А., Демидова О.А., Аракелян В.С. и др. Опыт лечения хронической ишемии нижних конечностей с помощью генного препарата сосудисто-эндотелиального фактора роста VEGF165 - ангиостимулина. Бюллетень НЦССХ им. А.Н. Баку- лева РАМН «Сердечно-сосудистые заболевания» 2006; 7(1): 74-81.
- Бочков Н.П., Константинов Б.А., Гавриленко А.В. и др. Генно- инженерные технологии в лечении хронической ишемии нижних конечностей. Вестник РАМН 2006; 9-10: 6-11.
- Константинов Б.А., Бочков Н.П., Гавриленко А.В. и др. Экс- периментальные и клинические результаты использования генно- инженерных конструкций с геном ангиогенина в лечении хронической ишемии нижних конечностей. Медицинская генетика 2005;4(7): 327-31.
- Lederman R.J., Mendelsohn F.O., Anderson R.D. et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC study). Lancet 2002; 359:2053-8.
- Makinen K., Manninen H., Hedman M. et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol. Ther. 2002; 6: 127-33.
- Rajagopalan S., Mohler E.R., Lederman R.J. et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease. Circulation 2003; 108: 1933-8.
Supplementary files
